Biohaven Ltd. (NYSE:BHVN) does about 1.31M shares in volume on a normal day but saw 1526358 shares change hands in Monday trading. The company now has a market cap of 1.31B USD. Its current market price is $19.20, marking an increase of 4.12% compared to the previous close of $18.44. The 52 week high reached by this stock is $18.78 whilst the lowest price level in 52 weeks is $5.54. The script in recent trading has seen the stock touch a high of $20.00 and a low of $18.27.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Biohaven Ltd. (BHVN) has a 20-day trading average at $15.52 and the current price is 2.24% off the 52-week high compared with 246.57% distance from its 52-week low. The 50-day simple moving average of the closing price is $15.40. If we look at the stock’s price movements over the week, volatility stands at 9.58%, which decreases to 8.89% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 65.79 to suggest the stock is neutral.
7 analysts observing the Biohaven Ltd. (BHVN) stock have set the 12-month price targets for the company’s shares at between $21.00 and $160.00. The consensus objective for the share price is $24.25, suggesting that the stock has a potential upside of 20.82% over the period. The median price target is 21.63% away from the current levels at $24.50.
FactSet Research has provided data showing that 7 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 7 analysts have rated it as a buy and 0 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on January 04, 2023 when JP Morgan initiated the stock to “Overweight” and issued a price target of $23. Cantor Fitzgerald upgraded its price target at $158-$27.
The current price level is 26.00%, 25.30%, and 37.50% away from its SMA20, SMA50, and SMA200 respectively, with the BHVN price moving below the 50-day SMA on January 23. Biohaven Ltd. (BHVN) stock is up 2.67% over the week and 36.07% over the past month. Its price is 38.33% year-to-date.
The company’s next earnings report is expected on 05/31/2023, with forecasts estimating quarterly EPS at -$2.34 and -$11.55 for whole year.
Its 12-month price target is $24.50. To reach the target analysts have set, the stock logically needs to grow 20.82 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $21.00, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $160.00.
Outstanding shares total 68.16M with insiders holding 7.40% of the shares and institutional holders owning 3.63% of the company’s common stock. Price to book ratio is 13.06.
According to a U.S. Securities and Exchange Commission filing, SPDR S&P Biotech ETF has added its position in Biohaven Ltd. (BHVN) to 3,535,063 shares, mirroring a recent increase by 0.41%. SPDR S&P Biotech ETF added 14288.0 shares of Biohaven Ltd. common stock bringing its total worth to about $49.07 million at the end of recent close, SEC documents show. SPDR S&P Biotech ETF isn’t the only investment manager who changed stakes and is followed by Fidelity Select Port – Biotechno, which sold off -0.86 million shares to end up with 2,823,752 shares worth $39.19 million. iShares Russell 2000 ETF cut their holdings by -1.03% in the company over the course of the most recent quarter. It now holds a 2.06% position in Biohaven Ltd. thanks to 1.41 million shares amounting to $19.52 million.
